A disintegrin and metalloprotease with a thrombospondin type 1 motifs 13 (ADAMTS-13) regulates hemostasis by cleaving the folded A2 domain of von Willebrand factor (VWF). The cleavage is regulated by forces as it occurs in flowing blood. We tested the hypothesis that force-induced A2 domain unfolding facilitates cleavage using atomic force microscopy to pull single VWF A1A2A3 tridomain polypeptides by platelet glycoprotein Ibalpha or antibodies to measure time, distance, and force. Structural destabilization of A1A2A3 was induced by 5- to 80-pN forces, manifesting as an abrupt molecular length increase distributed around 20 and 50 nm, probably because of uncoupling A1A2A3 (or partially unfolding A2) and fully unfolding A2, respectively. Time required to destabilize A1A2A3 first increased (catch), reaching a maximum of 0.2 seconds at 20pN, then decreased (slip) with increasing force, independent of ADAMTS-13. The time required to rupture A1A2A3 exhibited a similar catch-slip behavior when pulled by glycoprotein Ibalpha but only slip behavior when pulled by antibody, which was progressively shortened by increasing concentration of ADAMTS-13 after (but not before) structural destabilization, indicating that cleavage of A2 requires the force-induced A2 unfolding. Analysis with a model for single-substrate trimolecular enzymatic kinetics estimated a cleavage rate k(cat) of 2.9 (+/- 59) seconds and a K(d) of 5.6 (+/- 3.4) nM for ADAMTS-13/A1A2A3 binding. These findings quantify the mechanical regulation of VWF cleavage by ADAMTS-13 at the level of single A1A2A3 tridomain.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808159 | PMC |
| http://dx.doi.org/10.1182/blood-2009-03-210369 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How Electricity Prevents Us from Bleeding to Death.
Rev Physiol Biochem Pharmacol
January 2025
Institute of Medical Sciences, University of Aberdeen, Aberdeen, Scotland, UK.
Rapid tissue repair is also needed in the event of damage to blood vessels. Most of the essential steps that prevent us from bleeding to death involve the functions of Von Willebrand factor (VWF) and many of these are dependent on electrical forces.
View Article and Find Full Text PDFA mutant complement factor H (W1183R) enhances proteolytic cleavage of von Willebrand factor by ADAMTS-13 under shear.
J Thromb Haemost
January 2025
Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA; Institute of Reproductive Medicine and Developmental Sciences, The University of Kansas Medical Center, Kansas City, KS 66160, USA. Electronic address:
Background: A loss-of-functional mutation (W1183R) in human complement factor H (CFH) is associated with complement-associated hemolytic uremic syndrome; mice carrying a similar mutation (W1206R) in CFH also develop thrombotic microangiopathy but its plasma von Willebrand factor (VWF) multimer sizes were dramatically reduced. The mechanism underlying such a dramatic change in plasma VWF multimer distribution in these mice is not fully understood.
Objectives: To determine the VWF and CFH interaction and how CFH proteins affect VWF multimer distribution.
Mechanistic insight into multiple antibody binding to ADAMTS13 in immune thrombotic thrombocytopenic purpura.
Res Pract Thromb Haemost
October 2024
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Article Synopsis
- Antibody-mediated inhibition of ADAMTS-13, a protein critical for blood clotting, leads to immune thrombotic thrombocytopenic purpura (iTTP), but the impact of multiple antibodies on this process is not fully understood.
- The study examines how different antibodies interact with ADAMTS-13 and finds that while both stimulatory and inhibitory antibodies can bind simultaneously, the inhibition prevails when both are present.
- Results suggest that these antibodies modify ADAMTS-13's catalytic activity through allosteric changes, indicating potential pathways for developing new diagnostic and therapeutic strategies for managing iTTP.
Excessive cleavage of von Willebrand factor multimers by ADAMTS13 may predict the progression of transplant-associated thrombotic microangiopathy.
Res Pract Thromb Haemost
July 2024
Department of Blood Transfusion Medicine, Nara Medical University, Kashihara City, Nara, Japan.
Article Synopsis
- Transplant-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplants that causes severe blood-related issues and organ dysfunction due to small blood clots forming in circulation.
- This study examined changes in von Willebrand factor (VWF) in patients to understand its role in the development of TA-TMA, analyzing plasma samples from 14 patients post-transplant.
- Results indicated that patients with definite TMA showed unique VWF changes compared to those with probable TMA, highlighting a transition from bleeding risks to clotting tendencies based on VWF multimer profiles and degradation products.
Animal models for thrombotic thrombocytopenic purpura: a narrative review.
Ann Blood
September 2023
Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS, USA.
Background And Objective: Thrombotic thrombocytopenic purpura (TTP) is a potentially fatal blood disorder, resulting from severe deficiency of plasma ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin type 1 repeats, 13) activity. ADAMTS13 is crucial for normal hemostasis through proteolytic cleavage of ultra large von Willebrand factor (VWF). Since the discovery of ADAMTS13 in 2001, several animal models for TTP have been established.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!